挪威 -
挪威文 -
Statens legemiddelverk
hypoloc 5 mg
menarini international o.l. s.a. - nebivololhydroklorid - tablett - 5 mg
挪威 -
挪威文 -
Statens legemiddelverk
hypoloc comp 5 mg / 12.5 mg
menarini international o.l. sa - nebivololhydroklorid / hydroklortiazid - tablett, filmdrasjert - 5 mg / 12.5 mg
挪威 -
挪威文 -
Statens legemiddelverk
ketesse 25 mg
menarini international o.l. s.a. - deksketoprofentrometamol - tablett, filmdrasjert - 25 mg
挪威 -
挪威文 -
Statens legemiddelverk
migard 2.5 mg
menarini international o.l. s.a. - frovatriptan - tablett, filmdrasjert - 2.5 mg
挪威 -
挪威文 -
Statens legemiddelverk
orodek 25 mg
menarini international o.l. s.a. - deksketoprofentrometamol - tablett, filmdrasjert - 25 mg
挪威 -
挪威文 -
Statens legemiddelverk
zofenil comp 30 mg / 12.5 mg
menarini international o.l. s.a. - zofenoprilkalsium / hydroklortiazid - tablett, filmdrasjert - 30 mg / 12.5 mg
挪威 -
挪威文 -
Statens legemiddelverk
zofenil 30 mg
menarini international o.l. s.a. - zofenoprilkalsium - tablett, filmdrasjert - 30 mg
挪威 -
挪威文 -
Statens legemiddelverk
zilas 20 mg
menarini international o.l. sa - bilastin - tablett - 20 mg
欧盟 -
挪威文 -
EMA (European Medicines Agency)
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - fellesskapsmessige infeksjoner - antibakterielle midler for systemisk bruk, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.
欧盟 -
挪威文 -
EMA (European Medicines Agency)
invokana
janssen-cilag international nv - canagliflozin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5.